Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

IMUX

Immunic Inc

Jan 13 • 03:21PM ET

0.6838

+0.0223 3.37 %

Healthcare • Biotechnology • USA • NASD

Peers: FATE IOVA AGEN KPTI ADAP MCRB AFMD IMTX ALDX ZLAB

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.87	Insider Own	1.31%	Shs Outstand	120.28M	Perf Week	9.67%
Market Cap	82.25M	Forward P/E	-	EPS next Y	-0.33	Insider Trans	0.00%	Shs Float	118.71M	Perf Month	4.24%
Enterprise Value	47.91M	PEG	-	EPS next Q	-0.09	Inst Own	52.21%	Short Float	5.54%	Perf Quarter	-23.56%
Income	-103.05M	P/S	-	EPS this Y	38.11%	Inst Trans	4.07%	Short Ratio	4.68	Perf Half Y	-17.92%
Sales	0.00M	P/B	6.42	EPS next Y	45.96%	ROA	-195.41%	Short Interest	6.57M	Perf YTD	28.12%
Book/sh	0.11	P/C	2.34	EPS next 5Y	24.34%	ROE	-398.50%	52W High	1.39 -50.81%	Perf Year	-34.88%
Cash/sh	0.29	P/FCF	-	EPS past 3/5Y	36.56% 26.01%	ROIC	-969.85%	52W Low	0.51 35.08%	Perf 3Y	-50.45%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.33% 8.02%	Perf 5Y	-95.91%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	30.16%	Oper. Margin	-	ATR (14)	0.05	Perf 10Y	-99.83%
Dividend Ex-Date	-	Quick Ratio	1.31	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.76	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.31	EPS Q/Q	45.18%	SMA20	13.70%	Beta	1.60	Target Price	5.38
Payout	-	Debt/Eq	0.08	Sales Q/Q	-	SMA50	2.97%	Rel Volume	1.30	Prev Close	0.66
Employees	91	LT Debt/Eq	0.01	Earnings	Nov 13 BMO	SMA200	-18.47%	Avg Volume	1.41M	Price	0.68
IPO	Apr 17, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.28% -	Trades		Volume	1,657,064	Change	3.37%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-07-25	Initiated	Roth Capital	Buy	$3
Sep-29-25	Initiated	Chardan Capital Markets	Buy	$13
Mar-25-25	Initiated	William Blair	Outperform
Nov-25-24	Initiated	H.C. Wainwright	Buy	$10
Sep-09-24	Resumed	Leerink Partners	Outperform	$5
Aug-27-24	Initiated	B. Riley Securities	Buy	$6
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$5
Sep-19-22	Resumed	H.C. Wainwright	Buy	$26
Apr-15-21	Initiated	Aegis Capital	Buy	$55
Mar-24-21	Initiated	JMP Securities	Mkt Outperform	$55
Oct-02-20	Initiated	SVB Leerink	Outperform	$45
Aug-26-20	Initiated	Piper Sandler	Overweight	$71
Aug-07-20	Resumed	ROTH Capital	Buy	$64
Jul-20-20	Initiated	BMO Capital Markets	Outperform	$40
Jun-05-20	Initiated	Wedbush	Outperform	$59
May-11-20	Initiated	H.C. Wainwright	Buy	$45
Mar-25-20	Initiated	ROTH Capital	Buy	$44
Jul-11-19	Initiated	Chardan Capital Markets	Buy	$40

Show Previous Ratings

Jan-12-26 04:23AM	Immunic (IMUX) Reviews 2025 Performance and Highlights Upcoming Milestones, Shares Up 24.10% (Insider Monkey)
Jan-07-26 06:30AM	Immunic Highlights 2025 Accomplishments and Upcoming Milestones (PR Newswire) +10.67%
Nov-26-25 06:30AM	Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December (PR Newswire)
Nov-13-25 06:39AM	Immunic: Q3 Earnings Snapshot (Associated Press Finance) -6.24%
06:30AM	Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
09:33AM	Loading…
Nov-07-25 09:33AM	Datadog, Trade Desk upgraded: Wall Street's top analyst calls (The Fly)
Oct-29-25 06:30AM	Immunic to Participate in Industry and Investor Conferences in November (PR Newswire) -5.01%
Oct-01-25 06:30AM	Immunic to Participate in Scientific and Investor Conferences in October (PR Newswire) +8.89%
Sep-25-25 06:30AM	Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis (PR Newswire)
Sep-09-25 06:30AM	Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis (PR Newswire)
Sep-04-25 06:30AM	Immunic to Participate in Investor and Scientific Conferences in September (PR Newswire)
Aug-07-25 06:37AM	Immunic: Q2 Earnings Snapshot (Associated Press Finance) -7.87%
06:30AM	Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Jul-25-25 12:22PM	Immunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS Trial (Insider Monkey)
Jun-24-25 06:30AM	Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis (PR Newswire)
06:30AM	Loading…
Jun-05-25 06:30AM	Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS (PR Newswire)
Jun-03-25 04:01PM	Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering (PR Newswire) +6.11%
Jun-02-25 06:30AM	Immunic to Participate in Investor, Scientific and Industry Conferences in June (PR Newswire) +6.08%
May-29-25 07:05AM	Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering (PR Newswire) -25.28%
May-28-25 04:02PM	Immunic, Inc. Announces Proposed Public Offering (PR Newswire)
May-15-25 06:24PM	Immunic: Q1 Earnings Snapshot (Associated Press Finance)
May-02-25 06:30AM	Immunic to Participate in Scientific and Industry Conferences in May (PR Newswire)
May-01-25 01:56PM	Immunic presses ahead with MS drug despite Phase II endpoint miss (Clinical Trials Arena) +18.17%
Apr-30-25 07:30AM	Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial (PR Newswire) -22.65%
Apr-28-25 02:09AM	Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher (Seeking Alpha)
Apr-10-25 01:00PM	Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments (PR Newswire)
Apr-09-25 08:10AM	Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments (PR Newswire)
Apr-01-25 06:30AM	Immunic, Inc. to Participate in Scientific and Industry Conferences in April (PR Newswire)
Mar-03-25 06:30AM	Immunic to Participate in Scientific and Investor Conferences in March (PR Newswire)
Feb-26-25 06:30AM	Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis (PR Newswire)
07:30AM	Loading…
Feb-20-25 07:30AM	Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing (PR Newswire) +12.38%
Feb-04-25 06:30AM	Immunic to Participate in Investor and Scientific Conferences in February (PR Newswire)
Jan-07-25 06:30AM	Immunic Highlights 2024 Accomplishments and Upcoming Milestones (PR Newswire)
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESS Newswire) -9.29%
Nov-26-24 06:30AM	Immunic, Inc. to Participate in Investor Conference in December (PR Newswire)
Nov-14-24 06:35AM	Immunic announces publication of IMU-856 data (TipRanks) -6.84%
Nov-13-24 06:30AM	Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology (PR Newswire)
Nov-09-24 08:00AM	Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges (GuruFocus.com)
Nov-07-24 06:41AM	Immunic: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Oct-31-24 06:30AM	Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update (PR Newswire)
Oct-29-24 06:30AM	Immunic to Participate in Industry, Scientific and Investor Conferences in November (PR Newswire)
Oct-22-24 06:30AM	Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis (PR Newswire) -9.68%
Oct-09-24 05:31PM	Immunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ... (GuruFocus.com) -6.67%
Sep-18-24 06:30AM	Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis (PR Newswire) +11.18%
Sep-04-24 06:30AM	Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome (PR Newswire)
Aug-28-24 06:30AM	Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September (PR Newswire)
Aug-08-24 06:34AM	Immunic: Q2 Earnings Snapshot (Associated Press Finance) +14.53%
06:30AM	Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Aug-01-24 06:30AM	Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update (PR Newswire)
Jul-24-24 06:30AM	Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec (PR Newswire) -5.48%
Jul-09-24 06:30AM	Immunic Appoints Jason Tardio as Chief Operating Officer and President (PR Newswire) +7.76%
May-30-24 07:03AM	Immunic Inc. CEO Daniel Vitt Highlights Advances in MS Treatment on World MS Day (News Direct)
May-28-24 06:30AM	Immunic to Participate in Industry and Scientific Conferences in June (PR Newswire)
May-23-24 06:00AM	Peek Behind the Curtain: 7 Penny Stocks With Heavy Insider Buying (InvestorPlace)
May-20-24 10:00AM	Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day (News Direct)
May-17-24 02:35PM	Immunic chief medical officer discusses promising treatments to mark World IBD Day (News Direct)
May-16-24 05:54PM	Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day (News Direct)
May-09-24 10:23AM	Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:58AM	Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones (News Direct)
May-08-24 06:36AM	Immunic: Q1 Earnings Snapshot (Associated Press Finance) -7.97%
06:30AM	Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-06-24 06:30AM	Immunic to Participate in Investor and Scientific Conferences in May (PR Newswire)
May-01-24 10:02AM	Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal (News Direct)
06:30AM	Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update (PR Newswire)
Apr-30-24 06:30AM	Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology Neuroimmunology & Neuroinflammation (PR Newswire)
Apr-29-24 11:11AM	Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role (News Direct)
Apr-04-24 06:30AM	Immunic to Host MS R&D Day and Participate in Investor Conferences in April (PR Newswire)
Mar-21-24 12:14PM	Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month (News Direct)
11:37AM	Immunic secures key patent, boosting MS drug exclusivity and global IP strategy (News Direct)
Mar-20-24 06:30AM	Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States (PR Newswire)
Mar-08-24 06:53AM	Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024 (News Direct)
Mar-07-24 06:30AM	Immunic to Participate in Investor and Scientific Conferences in March (PR Newswire)
Feb-29-24 06:30AM	Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 (PR Newswire)
Feb-23-24 09:02PM	Immunic Inc (IMUX) Reports Year-End 2023 Financial Results (GuruFocus.com)
11:04AM	Immunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 10:59AM	Immunic reports successful 2023 and prepares for key 2025 milestones (News Direct)
06:30AM	Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update (PR Newswire)
Feb-15-24 06:30AM	Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update (PR Newswire)
Feb-01-24 06:30AM	Immunic to Participate in Investor and Scientific Conferences in February (PR Newswire)
Jan-05-24 06:35AM	Immunic Highlights 2023 Accomplishments and Upcoming Milestones (PR Newswire)
06:30AM	Immunic, Inc. Announces Private Placement of up to $240 Million (PR Newswire)
Nov-21-23 06:30AM	Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis (PR Newswire)
Nov-14-23 01:25PM	Immunic focusing on business development during Q4 (News Direct)
06:36AM	Immunic: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-07-23 06:30AM	Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update (PR Newswire)
Nov-02-23 06:30AM	Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts (PR Newswire)
Oct-26-23 06:30AM	Immunic to Participate in Scientific and Industry Conferences in November (PR Newswire)
Oct-24-23 07:51AM	Immunic CSO hails "great" progress with MS program (News Direct)
Oct-16-23 06:30AM	Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023 (PR Newswire)
Oct-15-23 06:30AM	Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023 (PR Newswire)
Oct-11-23 06:30AM	Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting (PR Newswire)
05:15AM	Immunic "super excited" about latest PMS trial data (News Direct)
Oct-10-23 09:07AM	Immunic's investors appeased by interim biomarker data from phase 2 MS trial (FierceBiotech.com) -13.84%
Oct-09-23 04:01PM	Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis (PR Newswire)
Oct-04-23 06:30AM	Immunic to Participate in Scientific Conferences in October (PR Newswire)
Sep-06-23 06:30AM	Immunic to Participate in Industry and Investor Conferences in September (PR Newswire)
Aug-21-23 08:00AM	Immunic CEO hails "great day" after completing IMU-838 phase 2 trial enrolment (News Direct)
Aug-17-23 06:30AM	Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis (PR Newswire)

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm's products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nash Duane	Executive Chairman	Jun 13 '25	Buy	0.83	20,000	16,694	36,032	Jun 16 05:00 PM
Tardio Jason	President and COO	Jun 05 '25	Buy	0.79	12,512	9,884	12,512	Jun 09 04:07 PM
Vitt Daniel	CEO and Director	Jun 04 '25	Buy	0.77	15,000	11,550	29,000	Jun 06 05:00 PM
Neermann Joerg	Director	Jun 04 '25	Buy	0.77	70,000	53,900	170,000	Jun 05 04:07 PM
Neermann Joerg	Director	Jun 05 '25	Buy	0.76	30,000	22,800	200,000	Jun 05 04:07 PM
Whaley Glenn	Chief Financial Officer	Jun 03 '25	Buy	0.71	45,000	32,076	95,510	Jun 04 04:22 PM
Rudick Richard Alan	Director	Jun 03 '25	Buy	0.70	143,075	100,024	230,375	Jun 04 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMUX

Immunic Inc

Upgrade your FINVIZ experience